(Q47386956)

15 January 2018

title

Grade 4 Events Are as Important as AIDS Events in the Era of HAART (English)

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

1 April 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615655

highly active antiretroviral therapy

1 April 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615655

1 April 2024

author name string

Cong Han

2

1 reference

15 January 2018

Ronald B. Reisler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615655

1 April 2024

William J. Burman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615655

1 April 2024

Ellen M. Tedaldi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615655

1 April 2024

James D. Neaton

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615655

1 April 2024

language of work or name

English

0 references

publication date

1 December 2003

1 reference

15 January 2018

Journal of Acquired Immune Deficiency Syndromes

published in

1 reference

15 January 2018

volume

34

1 reference

15 January 2018

issue

4

1 reference

15 January 2018

page(s)

379-386

1 reference

15 January 2018

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

cites work

2

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 April 2024

3

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 April 2024

4

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Toward HIV eradication or remission: the tasks ahead.

1 April 2024

5

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

1 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Time to hit HIV, early and hard.

1 April 2024

7

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Latent reservoirs of HIV: obstacles to the eradication of virus

1 April 2024

8

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 April 2024

9

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 April 2024

10

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

1 April 2024

11

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Inhibition of natural killer cell cytotoxicity and interferon gamma production by the envelope protein of HIV and prevention by vasoactive intestinal peptide

1 April 2024

13

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Direct role of plasma membrane-expressed gp120/41 in toxicity to human astrocytes induced by HIV-1-infected macrophages

1 April 2024

14

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Mitochondrial control of cell death induced by HIV-1-encoded proteins

1 April 2024

15

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Cutaneous disease and drug reactions in HIV infection

1 April 2024

16

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy

1 April 2024

18

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

1 April 2024

19

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

1 April 2024

20

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Individualising HIV treatment--pharmacogenetics and immunogenetics

1 April 2024

22

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review

1 April 2024

23

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Age as a determinant of survival in HIV infection

1 April 2024

24

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

High prevalence of iron deficiency and anemia among female injection drug users with and without HIV infection

1 April 2024

25

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Anemia in HIV-infected patients receiving highly active antiretroviral therapy

1 April 2024

26

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women

1 April 2024

27

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study

1 April 2024

28

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Iron status and the outcome of HIV infection: an overview

1 April 2024

29

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era.

1 April 2024

33

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses

1 April 2024

34

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

1 April 2024

35

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy

1 April 2024

36

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 April 2024

37

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 April 2024

38

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

1 April 2024

39

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

1 April 2024

41

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

The burden of malaria in pregnancy in malaria-endemic areas.

1 April 2024

42

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

1 April 2024

43

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

1 April 2024

44

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

HIV drug interactions: the good, the bad, and the other.

1 April 2024

45

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Drug Interactions with Antiretrovirals

1 April 2024

46

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS.

1 April 2024

48

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

HIV status and sociodemographic correlates of maternal body size and wasting during pregnancy

1 April 2024

49

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

When obesity is desirable: a longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort

1 April 2024

52

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients

1 April 2024

53

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic

1 April 2024

54

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy

1 April 2024

55

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection

1 April 2024

56

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study

1 April 2024

57

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Lack of legal income is strongly associated with an increased risk of AIDS and death in HIV-infected injecting drug users

1 April 2024

58

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Progression to AIDS: the effects of stress, depressive symptoms, and social support

1 April 2024

59

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS.

1 April 2024

60

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy

1 April 2024

61

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival

1 April 2024

62

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial.

1 April 2024

63

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS

1 April 2024

64

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

1 April 2024

66

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Experience with a cross-study endpoint review committee for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS

1 April 2024

67

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinica

1 April 2024

68

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Timing of new black box warnings and withdrawals for prescription medications

1 April 2024

69

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas

1 April 2024

70

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Reporting of Adverse Effects in Clinical Trials Should Be Improved

1 April 2024

71

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 April 2024

72

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction

1 April 2024

73

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages

1 April 2024

74

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Central nervous system adverse effects with efavirenz: case report and review

1 April 2024

75

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

Association between efavirenz and selected psychiatric and neurological conditions

1 April 2024

76

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial

1 April 2024

78

1 reference

https://api.crossref.org/works/10.1097/00126334-200312010-00004

1 April 2024

Identifiers

1 reference

15 January 2018

1 reference

15 January 2018